Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis
Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects o...
Saved in:
| Published in | Scientific reports Vol. 12; no. 1; pp. 4456 - 22 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
15.03.2022
Nature Publishing Group Nature Portfolio |
| Subjects | |
| Online Access | Get full text |
| ISSN | 2045-2322 2045-2322 |
| DOI | 10.1038/s41598-022-08400-z |
Cover
| Abstract | Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77],
P
= 0.0002), shorter stimulation duration (WMD = − 0.91; 95% CI: [-1.45 to − 0.37] day,
P
= 0.0009), lower gonadotropin consumption (WMD = − 221.36; 95% CI: [− 332.28 to − 110.45] IU,
P
< 0.0001), lower E2 levels on hCG day (WMD = − 259.21; 95% CI: [− 485.81 to − 32.60] pg/ml,
P
= 0.02), thinner endometrial thickness on hCG day (WMD = − 0.73; 95% CI: [− 1.17 to − 0.29] mm,
P
= 0.001), and lower number of retrieved oocytes (WMD = − 1.82; 95% CI: [− 3.48 to − 0.15] oocytes,
P
= 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41],
P
= 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476). |
|---|---|
| AbstractList | Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = - 0.91; 95% CI: [-1.45 to - 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = - 221.36; 95% CI: [- 332.28 to - 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = - 259.21; 95% CI: [- 485.81 to - 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = - 0.73; 95% CI: [- 1.17 to - 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = - 1.82; 95% CI: [- 3.48 to - 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476). Abstract Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = − 0.91; 95% CI: [-1.45 to − 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = − 221.36; 95% CI: [− 332.28 to − 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = − 259.21; 95% CI: [− 485.81 to − 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = − 0.73; 95% CI: [− 1.17 to − 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = − 1.82; 95% CI: [− 3.48 to − 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476). Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = − 0.91; 95% CI: [-1.45 to − 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = − 221.36; 95% CI: [− 332.28 to − 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = − 259.21; 95% CI: [− 485.81 to − 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = − 0.73; 95% CI: [− 1.17 to − 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = − 1.82; 95% CI: [− 3.48 to − 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476). Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = − 0.91; 95% CI: [-1.45 to − 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = − 221.36; 95% CI: [− 332.28 to − 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = − 259.21; 95% CI: [− 485.81 to − 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = − 0.73; 95% CI: [− 1.17 to − 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = − 1.82; 95% CI: [− 3.48 to − 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476). Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = - 0.91; 95% CI: [-1.45 to - 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = - 221.36; 95% CI: [- 332.28 to - 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = - 259.21; 95% CI: [- 485.81 to - 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = - 0.73; 95% CI: [- 1.17 to - 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = - 1.82; 95% CI: [- 3.48 to - 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476).Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro Fertilization/ Intra-Cytoplasmic Sperm Injection (IVF/ICSI) cycles. This review aimed to summarize the available evidence comparing the effects of conventional GnRH antagonist protocols, the most commonly used GnRH antagonist protocols, and GnRH agonist protocols on IVF/ICSI outcomes in women with polycystic ovary syndrome (PCOS). A comprehensive electronic search was carried out in Pubmed, Cochrane CENTRAL, Scopus, Web of Science, CINAHL, TRIP, ClinicalTrials.gov and ISRCTN registry from inception until 24 November 2020 without any language or date restrictions. In addition, reference lists of eligible studies and previous meta-analyses were hand-searched to identify relevant studies. Eligible randomized controlled trials were those designed to compare the effects of conventional GnRH antagonist protocols and GnRH agonist protocols on IVF/ICSI outcomes in PCOS subjects. The Cochrane ROB 2.0 tool was used to assess the risk of bias of each study, and the GRADE assessment was used to evaluate the overall quality of evidence. Data synthesis and analyses were done using Review Manager 5.3 with the assistance of Revman Web. A random-effects model was used for all meta-analysis. Dichotomous outcomes were reported as Relative Risk (RR) and continuous outcomes as Weighted Mean Difference (WMD), both with 95% CIs. The primary outcomes were Live birth rate, Ongoing pregnancy rate, and Ovarian hyperstimulation syndrome (OHSS) rate. Other IVF outcomes were considered secondary outcomes. We included ten studies with 1214 randomized PCOS women. Using GnRH antagonist protocols led to a significantly lower OHSS rate (RR = 0.58; 95% CI: [0.44 to 0.77], P = 0.0002), shorter stimulation duration (WMD = - 0.91; 95% CI: [-1.45 to - 0.37] day, P = 0.0009), lower gonadotropin consumption (WMD = - 221.36; 95% CI: [- 332.28 to - 110.45] IU, P < 0.0001), lower E2 levels on hCG day (WMD = - 259.21; 95% CI: [- 485.81 to - 32.60] pg/ml, P = 0.02), thinner endometrial thickness on hCG day (WMD = - 0.73; 95% CI: [- 1.17 to - 0.29] mm, P = 0.001), and lower number of retrieved oocytes (WMD = - 1.82; 95% CI: [- 3.48 to - 0.15] oocytes, P = 0.03). However, no significant differences in live birth rate, ongoing pregnancy rate, clinical pregnancy rate, multiple pregnancy rate, miscarriage rate and cycle cancellation rate were seen between the GnRH antagonist protocols and the long GnRH agonist one. Although more cycles were cancelled due to poor ovarian response in the GnRH antagonist protocol (RR = 4.63; 95% CI: [1.49 to 14.41], P = 0.008), similar rates of cancellation due to risk of OHSS were noticed in both groups. The differences in IVF/ICSI outcomes may arise from the different patterns of gonadotropins suppression that the GnRH analogues exhibit during the early follicular phase of IVF/ICSI cycles and the divergent direct impacts of these analogues on ovaries and endometrial receptivity. The main evidence limitation was Imprecision. Conventional GnRH antagonist protocols represent a safer and more cost-effective treatment choice for PCOS women undergoing IVF/ICSI cycles than the standard long GnRH agonist protocol without compromising the IVF/ICSI clinical outcomes. The study had no sources of financial support and was prospectively registered at PROSPERO (International Prospective Register of Systematic Reviews) under registration number (CRD42021242476). |
| ArticleNumber | 4456 |
| Author | Alhalabi, Marwan Kadoura, Sally Nattouf, Abdul Hakim |
| Author_xml | – sequence: 1 givenname: Sally surname: Kadoura fullname: Kadoura, Sally email: sally.clinical@gmail.com organization: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University – sequence: 2 givenname: Marwan surname: Alhalabi fullname: Alhalabi, Marwan organization: Department of Embryology and Reproductive Medicine, Faculty of Medicine, Damascus University, Assisted Reproduction Unit, Orient Hospital – sequence: 3 givenname: Abdul Hakim surname: Nattouf fullname: Nattouf, Abdul Hakim organization: Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Damascus University |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35292717$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAUhSNUREvpC7BAltiwCfVvnLBAQiPajlQJib-tdeM4g0eOPdiZqdL34T3xdKbQzqJZONb1d46O7POyOPLBm6J4TfB7gll9njgRTV1iSktcc4zL22fFCcVclJRRevRgf1ycpbTE-RO04aR5URyzvKOSyJPizyz4jfGjDR4cuvRfrxD4ERbB2zSiVQxj0MEltDExrRNywS_21AGCrEfznxfn89m3OdKTdiah0KNVcJOe0mg1ChuIE0qT72IYDLrJi_-AIE_SaAbYItFsrLnJCTo0mBFKyKGmZNOr4nkPLpmz_f-0-HHx-fvsqrz-cjmffbouteB4LHssWl31DXApdaVxi4kAVkktRUtZyzTppQFJGfA8EoJhEJprQaCtZdu17LSY73y7AEu1inbIkVUAq-4GIS4UxBzUGaXrHmRDsDbM8Bp0DTUxfSd7wJXhsspeH3deq3U7mE7nS47gHpk-PvH2l1qEjaobyqmU2eDd3iCG32uTRjXYpI1z4E1YJ0Wr_Oy8Jg3P6NsDdBnWMV_elmINYTjDmXrzMNG_KPdtyEC9A3QMKUXTK21H2HYjB7ROEay23VO77qncPXXXPXWbpfRAeu_-pIjtRCnDfmHi_9hPqP4CAizwRQ |
| CitedBy_id | crossref_primary_10_1186_s13048_024_01437_w crossref_primary_10_7759_cureus_52597 crossref_primary_10_1210_clinem_dgae847 crossref_primary_10_1016_j_clinthera_2024_11_015 crossref_primary_10_1080_14656566_2024_2418985 crossref_primary_10_3389_fendo_2024_1309993 crossref_primary_10_1210_clinem_dgad397 crossref_primary_10_1186_s12958_023_01113_6 crossref_primary_10_12677_ACM_2024_143709 crossref_primary_10_1080_14647273_2024_2441827 crossref_primary_10_2147_JMDH_S432936 crossref_primary_10_3390_genes15121590 crossref_primary_10_1016_j_gine_2024_100970 crossref_primary_10_1016_j_heliyon_2023_e14518 crossref_primary_10_17116_rosakush20242406179 crossref_primary_10_62347_QKPV5157 crossref_primary_10_12998_wjcc_v11_i9_2067 crossref_primary_10_3389_fendo_2025_1507857 crossref_primary_10_1177_20420188231173325 crossref_primary_10_3389_fendo_2023_1224858 crossref_primary_10_1016_j_ejogrb_2024_11_028 crossref_primary_10_1007_s43032_024_01783_6 crossref_primary_10_1016_j_heliyon_2023_e23933 crossref_primary_10_1080_01443615_2023_2195937 crossref_primary_10_7759_cureus_61554 crossref_primary_10_3390_jpm14090915 crossref_primary_10_2196_53396 crossref_primary_10_1002_dta_3876 crossref_primary_10_1186_s12884_023_06112_4 crossref_primary_10_3389_fendo_2024_1457435 crossref_primary_10_1007_s00404_023_07047_z crossref_primary_10_1097_MED_0000000000000780 crossref_primary_10_4274_jtgga_galenos_2024_2023_12_9 crossref_primary_10_1016_j_eprac_2023_09_004 crossref_primary_10_3389_fphar_2024_1434625 crossref_primary_10_1186_s12958_023_01120_7 crossref_primary_10_1002_eng2_70008 crossref_primary_10_2147_IJWH_S500692 crossref_primary_10_7759_cureus_54912 crossref_primary_10_1186_s13048_024_01372_w crossref_primary_10_2174_0118715303281640240722070348 crossref_primary_10_1590_1984_3143_ar2023_0040 |
| Cites_doi | 10.1177/0962280219889080 10.1002/14651858.CD008046.pub4 10.1093/humrep/17.1.201 10.1093/hropen/hoy021 10.1186/s13293-018-0195-5 10.1093/humrep/del340 10.1093/humrep/dey119 10.1016/j.fertnstert.2012.07.760 10.1093/humrep/16.12.2533 10.1095/biolreprod67.4.1305 10.5653/cerm.2012.39.1.22 10.1016/j.fertnstert.2014.07.1265 10.1093/humupd/dmv029 10.1016/S0015-0282(02)04920-8 10.3109/09513590.2012.736561 10.1016/j.mjafi.2012.03.005 10.1016/S1472-6483(10)61115-7 10.1016/j.rbmo.2010.03.017 10.1186/1741-7015-8-41 10.1093/humrep/del215 10.1093/humrep/deh375 10.5653/cerm.2012.39.4.166 10.1080/14647270802621358 10.7863/jum.1999.18.4.303 10.1016/j.fertnstert.2009.09.032 10.1016/S1472-6483(10)60621-9 10.1186/1477-7827-11-20 10.1371/journal.pone.0091796 10.1016/j.ejogrb.2012.07.014 10.1093/humrep/dem033 10.1093/humupd/dmv059 10.1038/nrdp.2016.57 10.1530/REP-19-0578 10.4103/0974-1208.101019 10.1016/j.fertnstert.2008.07.1711 10.1016/j.fertnstert.2007.04.060 10.1007/s10815-008-9249-7 10.17772/gp/62205 10.1016/j.contraception.2004.12.017 10.1095/biolreprod.109.081299 10.4103/0974-1208.86080 10.1093/humrep/dei348 10.1016/j.rbmo.2011.09.017 10.1111/micc.12093 10.1002/uog.11187 10.1093/molehr/6.10.935 10.3389/fendo.2020.615957 10.1093/humupd/dmx017 10.1016/j.rbmo.2019.03.203 10.5653/cerm.2018.45.3.135 10.1016/j.jrhm.2014.10.001 10.1093/abbs/gmaa173 10.1093/humrep/dep291 10.1055/s-0042-100206 10.1016/j.fertnstert.2005.08.020 10.4103/GMIT.GMIT_112_18 10.1016/S1472-6483(10)60652-9 10.3109/09513590.2011.633661 10.1093/humrep/dei243 10.1016/j.fertnstert.2008.07.565 10.1186/s43043-019-0002-1 10.1177/1933719114561552 10.1093/humrep/den468 10.1016/j.ejogrb.2005.08.017 10.1016/S1472-6483(10)60420-8 10.1136/bmj.l4898 10.1111/j.1447-0756.2010.01247.x 10.1093/humrep/dep436 10.1038/374460a0 10.1007/s00404-012-2348-9 10.12659/MSM.913757 10.5152/balkanmedj.2011.019 10.1093/humrep/dey281 10.1016/0002-9378(95)90490-5 10.4103/0974-1208.130802 10.1093/humrep/deg516 10.1016/S0015-0282(16)55430-2 10.1177/1933719107310707 10.1016/j.mefs.2015.11.001 10.1186/gb-2005-6-2-209 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2022 2022. The Author(s). The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2022 – notice: 2022. The Author(s). – notice: The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88A 88E 88I 8FE 8FH 8FI 8FJ 8FK ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M2P M7P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
| DOI | 10.1038/s41598-022-08400-z |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Medical Database (Alumni Edition) Science Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central - New (Subscription) Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Medical Database Science Database Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database (subscription) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Sustainability ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Central Basic ProQuest Science Journals ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE Publicly Available Content Database MEDLINE - Academic CrossRef |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2045-2322 |
| EndPage | 22 |
| ExternalDocumentID | oai_doaj_org_article_c8fa7910ce3e48ac8a81efd7fa06e476 PMC8924277 35292717 10_1038_s41598_022_08400_z |
| Genre | Meta-Analysis Systematic Review Journal Article |
| GroupedDBID | 0R~ 3V. 4.4 53G 5VS 7X7 88A 88E 88I 8FE 8FH 8FI 8FJ AAFWJ AAJSJ AAKDD ABDBF ABUWG ACGFS ACSMW ACUHS ADBBV ADRAZ AENEX AEUYN AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BPHCQ BVXVI C6C CCPQU DIK DWQXO EBD EBLON EBS ESX FYUFA GNUQQ GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE KQ8 LK8 M0L M1P M2P M48 M7P M~E NAO OK1 PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM SNYQT UKHRP AASML AAYXX AFPKN CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 7XB 8FK K9. PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS Q9U 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c540t-f05bc6f9a477c6c0b015a367c75b23b3c1f7ea723a4c755530a5c4c51ab87bdb3 |
| IEDL.DBID | 7X7 |
| ISSN | 2045-2322 |
| IngestDate | Wed Aug 27 01:20:32 EDT 2025 Tue Sep 23 05:48:01 EDT 2025 Thu Sep 04 22:28:58 EDT 2025 Sat Aug 16 22:24:08 EDT 2025 Thu Jan 02 22:54:26 EST 2025 Thu Apr 24 23:00:36 EDT 2025 Tue Jul 01 01:34:48 EDT 2025 Fri Feb 21 02:39:11 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | 2022. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c540t-f05bc6f9a477c6c0b015a367c75b23b3c1f7ea723a4c755530a5c4c51ab87bdb3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.proquest.com/docview/2639130264?pq-origsite=%requestingapplication% |
| PMID | 35292717 |
| PQID | 2639130264 |
| PQPubID | 2041939 |
| PageCount | 22 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_c8fa7910ce3e48ac8a81efd7fa06e476 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8924277 proquest_miscellaneous_2640048194 proquest_journals_2639130264 pubmed_primary_35292717 crossref_citationtrail_10_1038_s41598_022_08400_z crossref_primary_10_1038_s41598_022_08400_z springer_journals_10_1038_s41598_022_08400_z |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-03-15 |
| PublicationDateYYYYMMDD | 2022-03-15 |
| PublicationDate_xml | – month: 03 year: 2022 text: 2022-03-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Scientific reports |
| PublicationTitleAbbrev | Sci Rep |
| PublicationTitleAlternate | Sci Rep |
| PublicationYear | 2022 |
| Publisher | Nature Publishing Group UK Nature Publishing Group Nature Portfolio |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group – name: Nature Portfolio |
| References | Behery, Hasan, Ali, Eltabakh (CR16) 2020; 24 Chen, Zheng (CR82) 2014; 21 Xu (CR92) 2018; 33 Onofriescu (CR57) 2013; 39 Khalaf (CR69) 2010; 21 Maggi (CR67) 2016; 22 CR39 Fanchin (CR20) 2003; 18 CR36 Sha, Wang, Cheng, Yan (CR7) 2019; 39 CR35 Fischer (CR15) 2016; 76 Hughes (CR8) 1992; 58 Wang, Hu, Yao, Sun (CR94) 2021; 53 Segal (CR58) 2008; 90 Cédrin-Durnerin (CR65) 2007; 22 Hwang (CR26) 2004; 19 Ashrafi (CR41) 2005; 3 CR48 Eryılmaz (CR10) 2012; 29 CR47 CR46 Kdous, Chaker, Bouyahia, Zhioua, Zhioua (CR56) 2009; 87 Copperman, Benadiva (CR9) 2013; 11 CR40 Xu (CR80) 2005; 71 Liu, Hartman, Hartman, Luo, Mahutte (CR100) 2018; 33 Pundir, Sunkara, El-Toukhy, Khalaf (CR31) 2012; 24 Hosseini (CR60) 2010; 36 Minaretzis (CR72) 1995; 172 Simon (CR96) 2005; 20 Teede, Deeks, Moran (CR2) 2010; 8 Vrtačnik-Bokal (CR49) 2009; 18 Kudsy, Alhalabi, Al-quobaili (CR88) 2016; 21 Youssef (CR33) 2014 Orvieto (CR53) 2012; 28 McDonnell, Hart (CR5) 2017; 13 Pan, Wu, Cheng, Li, Chang (CR85) 2002; 17 Kara, Ozcan, Aran, Kara, Yilmaz (CR98) 2019; 8 CR51 Sterne (CR37) 2019; 366 Naredi, Talwar, Sandeep (CR84) 2014; 70 Mokhtar (CR23) 2015; 16 Lin (CR28) 2014; 9 Malhotra (CR76) 2015; 1 Palomba (CR6) 2015; 21 Schulte, Tsai, Moley (CR99) 2015; 22 Fanchin, Méndez Lozano, Schonäuer, Cunha-Filho, Frydman (CR21) 2005; 10 Chen, Zhao, Zhang (CR42) 2018; 24 Artini (CR89) 2009; 12 Ghaebi (CR17) 2018; 21 Zeinalzadeh (CR50) 2014; 12 Ghosh (CR83) 2000; 6 Winkler, Bukulmez, Hardy, Carr (CR70) 2010; 94 Haydardedeoglu, Kilicdag, Parlakgumus, Zeyneloglu (CR18) 2012; 286 Shin (CR27) 2018; 45 Ferrari, Pezzuto, Barusi, Coppola (CR75) 2006; 124 Rackow, Kliman, Taylor (CR90) 2008; 89 Holmes, Zachary (CR77) 2005; 6 Ruan (CR93) 2006; 21 Choi (CR45) 2012; 98 Namavar Jahromi (CR13) 2018; 43 Devroey (CR19) 2009; 24 Costello (CR3) 2019; 2019 Choi (CR43) 2005; 48 Kdous, M’solly, Zhioua, Meriah (CR55) 2008; 86 Lainas (CR25) 2007; 22 Kumar, Sait, Sharma, Kumar (CR12) 2011; 4 Metallinou, Asimakopoulos, Schröer, Nikolettos (CR68) 2007; 14 Alcázar, Kudla (CR87) 2012; 40 Azziz (CR1) 2016; 2 Lambalk (CR29) 2017; 23 Devroey (CR11) 2009; 24 Kolibianakis (CR66) 2006; 21 Kaur (CR54) 2012; 5 McGrath, Zhao, Steele, Thombs, Benedetti (CR38) 2020 Eddy, Bidwell, George (CR78) 2018; 9 Trenkić (CR63) 2016; 87 Hazzard, Xu, Stouffer (CR81) 2002; 67 Chen (CR91) 2020; 159 Lainas (CR62) 2010; 25 Sun (CR14) 2020; 11 Xiao, Chen, Zhang, Chang (CR30) 2013; 29 Bahçeci (CR59) 2005; 50 Hou, Taylor, Shu, Johnston-MacAnanny, Yalcinkaya (CR79) 2014; 102 Page (CR34) 2021; 372 Ultrasonography (CR86) 1999; 18 Huirne (CR64) 2006; 13 Orvieto (CR52) 2009; 91 Kolibianakis (CR22) 2003; 79 Griesinger, Diedrich, Tarlatzis, Kolibianakis (CR32) 2006; 13 Haouzi (CR97) 2010; 82 Kurzawa, Ciepiela, Baczkowski, Safranow, Brelik (CR61) 2008; 25 Giampietro, Sancilio, Tiboni, Rana, Di Pietro (CR73) 2006; 85 Garcia-Velasco (CR71) 2001; 16 Choi (CR44) 2012; 39 Lavorato (CR74) 2012; 165 Kim (CR24) 2012; 39 Satokata, Benson, Maas (CR95) 1995; 374 Tandulwadkar, Lodha, Mangeshikar (CR4) 2014; 7 MH Choi (8400_CR44) 2012; 39 EG Hughes (8400_CR8) 1992; 58 C Simon (8400_CR96) 2005; 20 MS Trenkić (8400_CR63) 2016; 87 EM Kolibianakis (8400_CR22) 2003; 79 JA Garcia-Velasco (8400_CR71) 2001; 16 B Namavar Jahromi (8400_CR13) 2018; 43 MAFM Youssef (8400_CR33) 2014 D Fischer (8400_CR15) 2016; 76 J Xiao (8400_CR30) 2013; 29 T Ultrasonography (8400_CR86) 1999; 18 B Xu (8400_CR92) 2018; 33 R McDonnell (8400_CR5) 2017; 13 M Kudsy (8400_CR88) 2016; 21 D Chen (8400_CR82) 2014; 21 H Lin (8400_CR28) 2014; 9 B Sun (8400_CR14) 2020; 11 M Kara (8400_CR98) 2019; 8 C Metallinou (8400_CR68) 2007; 14 R Orvieto (8400_CR52) 2009; 91 R Fanchin (8400_CR20) 2003; 18 EM Kolibianakis (8400_CR66) 2006; 21 H Teede (8400_CR2) 2010; 8 F Giampietro (8400_CR73) 2006; 85 D Haouzi (8400_CR97) 2010; 82 F Xu (8400_CR80) 2005; 71 L Hou (8400_CR79) 2014; 102 H Kaur (8400_CR54) 2012; 5 P Devroey (8400_CR11) 2009; 24 8400_CR36 8400_CR35 Q Chen (8400_CR91) 2020; 159 8400_CR39 OG Eryılmaz (8400_CR10) 2012; 29 MF Costello (8400_CR3) 2019; 2019 C-H Kim (8400_CR24) 2012; 39 B Haydardedeoglu (8400_CR18) 2012; 286 H Ruan (8400_CR93) 2006; 21 DI Holmes (8400_CR77) 2005; 6 MA Hosseini (8400_CR60) 2010; 36 R Azziz (8400_CR1) 2016; 2 M Ashrafi (8400_CR41) 2005; 3 R Fanchin (8400_CR21) 2005; 10 Y Chen (8400_CR42) 2018; 24 MMB Schulte (8400_CR99) 2015; 22 A Onofriescu (8400_CR57) 2013; 39 R Kurzawa (8400_CR61) 2008; 25 8400_CR51 H Pan (8400_CR85) 2002; 17 N Malhotra (8400_CR76) 2015; 1 M Kdous (8400_CR55) 2008; 86 S McGrath (8400_CR38) 2020 JW Choi (8400_CR43) 2005; 48 M Bahçeci (8400_CR59) 2005; 50 B Ferrari (8400_CR75) 2006; 124 P Kumar (8400_CR12) 2011; 4 G Griesinger (8400_CR32) 2006; 13 S Segal (8400_CR58) 2008; 90 PG Artini (8400_CR89) 2009; 12 NK Ghaebi (8400_CR17) 2018; 21 KE Liu (8400_CR100) 2018; 33 MH Choi (8400_CR45) 2012; 98 8400_CR40 D Ghosh (8400_CR83) 2000; 6 E Vrtačnik-Bokal (8400_CR49) 2009; 18 JAC Sterne (8400_CR37) 2019; 366 N Naredi (8400_CR84) 2014; 70 8400_CR48 8400_CR47 8400_CR46 TG Lainas (8400_CR62) 2010; 25 BW Rackow (8400_CR90) 2008; 89 MJ Page (8400_CR34) 2021; 372 S Mokhtar (8400_CR23) 2015; 16 JL Alcázar (8400_CR87) 2012; 40 JJ Shin (8400_CR27) 2018; 45 I Cédrin-Durnerin (8400_CR65) 2007; 22 R Maggi (8400_CR67) 2016; 22 J-L Hwang (8400_CR26) 2004; 19 M Kdous (8400_CR56) 2009; 87 HL Lavorato (8400_CR74) 2012; 165 T Sha (8400_CR7) 2019; 39 JAF Huirne (8400_CR64) 2006; 13 AC Eddy (8400_CR78) 2018; 9 AB Copperman (8400_CR9) 2013; 11 P Devroey (8400_CR19) 2009; 24 CB Lambalk (8400_CR29) 2017; 23 S Palomba (8400_CR6) 2015; 21 Y Wang (8400_CR94) 2021; 53 TG Lainas (8400_CR25) 2007; 22 R Orvieto (8400_CR53) 2012; 28 M Khalaf (8400_CR69) 2010; 21 SR Tandulwadkar (8400_CR4) 2014; 7 I Satokata (8400_CR95) 1995; 374 TM Hazzard (8400_CR81) 2002; 67 N Winkler (8400_CR70) 2010; 94 MA Behery (8400_CR16) 2020; 24 M Zeinalzadeh (8400_CR50) 2014; 12 J Pundir (8400_CR31) 2012; 24 D Minaretzis (8400_CR72) 1995; 172 |
| References_xml | – year: 2020 ident: CR38 article-title: Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysis publication-title: Stat. Methods Med. Res. doi: 10.1177/0962280219889080 – volume: 5 start-page: 181 year: 2012 end-page: 186 ident: CR54 article-title: A prospective study of GnRH long agonist versus flexible GnRH antagonist protocol in PCOS: Indian experience publication-title: J. Hum. Reprod. Sci. – volume: 12 start-page: 40 year: 2009 end-page: 44 ident: CR89 article-title: Vascular endothelial growth factor and its soluble receptor in patients with polycystic ovary syndrome undergoing IVF publication-title: Hum. Fertil. – ident: CR39 – volume: 6 start-page: 935 year: 2000 end-page: 941 ident: CR83 article-title: Expression of vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) in conceptus and endometrium during implantation in the rhesus monkey publication-title: Mol. Hum. Reprod. – ident: CR51 – volume: 172 start-page: 1518 year: 1995 end-page: 1525 ident: CR72 article-title: Gonadotropin-releasing hormone antagonist versus agonist administration in women undergoing controlled ovarian hyperstimulation: cycle performance and in vitro steroidogenesis of granulosa-lutein cells publication-title: Am. J. Obstet. Gynecol. – volume: 6 start-page: 209 year: 2005 ident: CR77 article-title: The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease publication-title: Genome Biol. – volume: 22 start-page: 109 year: 2007 end-page: 116 ident: CR65 article-title: Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol publication-title: Hum. Reprod. – volume: 14 start-page: 737 year: 2007 end-page: 749 ident: CR68 article-title: Gonadotropin-releasing hormone in the ovary publication-title: Reprod. Sci. – volume: 94 start-page: 1832 year: 2010 end-page: 1839 ident: CR70 article-title: Gonadotropin releasing hormone antagonists suppress aromatase and anti-Müllerian hormone expression in human granulosa cells publication-title: Fertil. Steril. – volume: 29 start-page: 187 year: 2013 end-page: 191 ident: CR30 article-title: Effectiveness of GnRH antagonist in the treatment of patients with polycystic ovary syndrome undergoing IVF: a systematic review and meta analysis publication-title: Gynecol. Endocrinol. – volume: 21 start-page: 52 year: 2016 end-page: 56 ident: CR88 article-title: Follicular fluid Vascular Endothelial Growth Factor (VEGF) could be a predictor for pregnancy outcome in normo-responders and polycystic ovary syndrome women undergoing IVF/ICSI treatment cycles publication-title: Middle East Fertil. Soc. J. – volume: 13 start-page: 628 year: 2006 end-page: 638 ident: CR32 article-title: GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis publication-title: Reprod. Biomed. Online – volume: 29 start-page: 197 year: 2012 end-page: 200 ident: CR10 article-title: Ovarian cyst formation following Gonadotropin-Releasing Hormone-Agonist administration decreases the oocyte quality in IVF cycles publication-title: Balkan Med. J. – volume: 76 start-page: 718 year: 2016 end-page: 726 ident: CR15 article-title: Avoiding OHSS: controlled ovarian low-dose stimulation in women with PCOS publication-title: Geburtshilfe Frauenheilkd. – volume: 85 start-page: 412 year: 2006 end-page: 419 ident: CR73 article-title: Levels of apoptosis in human granulosa cells seem to be comparable after therapy with a gonadotropin-releasing hormone agonist or antagonist publication-title: Fertil. Steril. – volume: 87 start-page: 834 year: 2009 end-page: 842 ident: CR56 article-title: Increased risk of earlypregnancy loss and lower live birth rate with GnRH antagonist vs long GnRH agonist protocol in PCOS women undergoing controlled ovarian hyperstimulation [Augmentation du taux de fausses couches spontanees precoces et diminution du t publication-title: Tunisie Med. – volume: 9 start-page: 36 year: 2018 ident: CR78 article-title: Pro-angiogenic therapeutics for preeclampsia publication-title: Biol. Sex Differ. – volume: 8 start-page: 41 year: 2010 ident: CR2 article-title: Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan publication-title: BMC Med. – volume: 165 start-page: 61 year: 2012 end-page: 65 ident: CR74 article-title: GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells publication-title: Eur. J. Obstet. Gynecol. Reprod. Biol. – ident: CR36 – volume: 11 start-page: 615957 year: 2020 ident: CR14 article-title: Factors associated with ovarian hyperstimulation syndrome (OHSS) severity in women with polycystic ovary syndrome undergoing IVF/ICSI publication-title: Front. Endocrinol. (Lausanne). – volume: 90 start-page: S232 year: 2008 ident: CR58 article-title: Comparison of outcomes between controlled ovarian stimulation with GnRH-agonist vs GnRH-antagonist for in vitro fertilization cycles in women with polycystic ovarian syndrome publication-title: Fertil. Steril. – volume: 79 start-page: 873 year: 2003 end-page: 880 ident: CR22 article-title: Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy publication-title: Fertil. Steril. – volume: 21 start-page: 1 year: 2018 end-page: 9 ident: CR17 article-title: Pregnancy outcomes in PCOS patients undergoing IVF with long GnRH agonist protocol versus flexible GnRH antagonist publication-title: Iran. J. Obstet. Gynecol. Infertil. – volume: 39 start-page: 22 year: 2012 end-page: 27 ident: CR24 article-title: Effectiveness of GNRH antagonist multiple dose protocol applied during early and late follicular phase compared with GNRH agonist long protocol in non-obese and obese patients with polycystic ovary syndrome undergoing IVF/ICSI publication-title: Clin. Exp. Reprod. Med. – volume: 24 start-page: 9424 year: 2018 end-page: 9428 ident: CR42 article-title: Comparative effectiveness of three ovarian hyperstimulation protocol in In Vitro Fertilization (IVF) cycles for women with Polycystic Ovary Syndrome publication-title: Med. Sci. Monit. – ident: CR47 – volume: 13 start-page: 235 year: 2006 end-page: 245 ident: CR64 article-title: Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study publication-title: Reprod. Biomed. Online – volume: 23 start-page: 560 year: 2017 end-page: 579 ident: CR29 article-title: GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type publication-title: Hum. Reprod. Update – volume: 2 start-page: 16057 year: 2016 ident: CR1 article-title: Polycystic ovary syndrome publication-title: Nat. Rev. Dis. Primers – volume: 10 start-page: 721 year: 2005 end-page: 728 ident: CR21 article-title: Hormonal manipulations in the luteal phase to coordinate subsequent antral follicle growth during ovarian stimulation publication-title: Reprod. Biomed. Online – volume: 67 start-page: 1305 year: 2002 end-page: 1312 ident: CR81 article-title: Injection of soluble vascular endothelial growth factor receptor 1 into the preovulatory follicle disrupts ovulation and subsequent luteal function in rhesus monkeys publication-title: Biol. Reprod. – volume: 89 start-page: 1234 year: 2008 end-page: 1239 ident: CR90 article-title: GnRH antagonists may affect endometrial receptivity publication-title: Fertil. Steril. – volume: 53 start-page: 365 year: 2021 end-page: 371 ident: CR94 article-title: Identification of HOXA10 target genes in human endometrial stromal cells by RNA-seq analysis publication-title: Acta Biochim. Biophys. Sin. (Shanghai) – volume: 374 start-page: 460 year: 1995 end-page: 463 ident: CR95 article-title: Sexually dimorphic sterility phenotypes in Hoxa10-deficient mice publication-title: Nature – volume: 18 start-page: 2698 year: 2003 end-page: 2703 ident: CR20 article-title: Luteal estradiol pre-treatment coordinates follicular growth during controlled ovarian hyperstimulation with GnRH antagonists publication-title: Hum. Reprod. – volume: 372 year: 2021 ident: CR34 article-title: The PRISMA 2020 statement: an updated guideline for reporting systematic reviews publication-title: BMJ – volume: 16 start-page: 148 year: 2015 end-page: 154 ident: CR23 article-title: ART outcomes in GnRH antagonist protocol (flexible) and long GnRH agonist protocol during early follicular phase in patients with polycystic ovary syndrome: a randomized clinical trial publication-title: J. Reprod. Infertil. – volume: 39 start-page: 166 year: 2012 end-page: 171 ident: CR44 article-title: Comparison of assisted reproductive technology outcomes in infertile women with polycystic ovary syndrome: In vitro maturation, gnrh agonist, and gnrh antagonist cycles publication-title: Clin. Exp. Reprod. Med. – year: 2014 ident: CR33 article-title: Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology publication-title: Cochrane Database Syst. Rev. doi: 10.1002/14651858.CD008046.pub4 – volume: 21 start-page: 2521 year: 2006 end-page: 2529 ident: CR93 article-title: Ovarian stimulation with GnRH agonist, but not GnRH antagonist, partially restores the expression of endometrial integrin β3 and leukaemia-inhibitory factor and improves uterine receptivity in mice publication-title: Hum. Reprod. – volume: 1 start-page: 41 year: 2015 end-page: 43 ident: CR76 article-title: Physiological balance between fVEGF and sVEGFR1 is maintained within ovarian follicles in normoresponder women irrespective of GnRH-agonist and GnRH-antagonist protocols publication-title: J. Reprod. Heal. Med. – volume: 86 start-page: 1060 year: 2008 end-page: 1065 ident: CR55 article-title: Use of GnRH antagonist (cetrorelix®) in controlled ovarian hyperstimulation in women with polycystic ovary disease [Utilisation des antagonistes de la GnRH (cetrorelix®) dans la stimulation plurifolliculaire chez les patientes porteuses d’une dystrophie o publication-title: Tunisie Med. – volume: 82 start-page: 679 year: 2010 end-page: 686 ident: CR97 article-title: Controlled ovarian hyperstimulation for In Vitro Fertilization alters endometrial receptivity in humans: protocol effects publication-title: Biol. Reprod. – volume: 18 start-page: 21 year: 2009 end-page: 28 ident: CR49 article-title: Follicular oestradiol and VEGF after GnRH antagonists or GnRH agonists in women with PCOS publication-title: Reprod. Biomed. Online – volume: 24 start-page: 6 year: 2012 end-page: 22 ident: CR31 article-title: Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? publication-title: Reprod. Biomed. Online – ident: CR35 – volume: 58 start-page: 888 year: 1992 end-page: 896 ident: CR8 article-title: The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials publication-title: Fertil. Steril. – volume: 21 start-page: 15 year: 2014 end-page: 25 ident: CR82 article-title: Regulation of placental angiogenesis publication-title: Microcirculation – volume: 40 start-page: 470 year: 2012 end-page: 475 ident: CR87 article-title: Ovarian stromal vessels assessed by spatiotemporal image correlation–high definition flow in women with polycystic ovary syndrome: a case–control study publication-title: Ultrasound Obstet. Gynecol. – volume: 4 start-page: 70 year: 2011 end-page: 75 ident: CR12 article-title: Ovarian hyperstimulation syndrome publication-title: J. Hum. Reprod. Sci. – ident: CR46 – volume: 12 start-page: 58 year: 2014 ident: CR50 article-title: Comparison of GnRH agonists and antagonists in the outcome of IVF/ICSI in women with polycystic ovary syndrome publication-title: Iran. J. Reprod. Med. – volume: 48 start-page: 716 year: 2005 end-page: 725 ident: CR43 article-title: Efficacy of controlled ovarian hyperstimulation using GnRH antagonist in women with polycystic ovary syndrome undergoing IVF-ET publication-title: Korean J Obs. Gynecol – volume: 19 start-page: 1993 year: 2004 end-page: 2000 ident: CR26 article-title: Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study publication-title: Hum. Reprod. – volume: 25 start-page: 683 year: 2010 end-page: 689 ident: CR62 article-title: Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: A prospective randomised controlled trial (RCT) publication-title: Hum. Reprod. – volume: 45 start-page: 135 year: 2018 end-page: 142 ident: CR27 article-title: Early gonadotropin-releasing hormone antagonist protocol in women with polycystic ovary syndrome: a preliminary randomized trial publication-title: Clin. Exp. Reprod. Med. – volume: 28 start-page: 422 year: 2012 end-page: 424 ident: CR53 article-title: Does day-3 LH/FSH ratio influence in vitro fertilization outcome in PCOS patients undergoing controlled ovarian hyperstimulation with different GnRH-analogue publication-title: Gynecol. Endocrinol. – volume: 13 start-page: 89 year: 2017 end-page: 97 ident: CR5 article-title: Pregnancy-related outcomes for women with polycystic ovary syndrome publication-title: Women’s Heal. – volume: 33 start-page: 1270 year: 2018 end-page: 1280 ident: CR92 article-title: Increased AIF-1-mediated TNF-α expression during implantation phase in IVF cycles with GnRH antagonist protocol publication-title: Hum. Reprod. – volume: 36 start-page: 605 year: 2010 end-page: 610 ident: CR60 article-title: Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients publication-title: J. Obstet. Gynaecol. Res. – volume: 24 start-page: 3063 year: 2009 end-page: 3072 ident: CR19 article-title: A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol publication-title: Hum. Reprod. – volume: 22 start-page: 6 year: 2015 end-page: 14 ident: CR99 article-title: Obesity and PCOS: the effect of metabolic derangements on endometrial receptivity at the time of implantation publication-title: Reprod. Sci. – volume: 22 start-page: 1540 year: 2007 end-page: 1546 ident: CR25 article-title: Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: Effect on hormonal levels and follicular development publication-title: Hum. Reprod. – volume: 71 start-page: 239 year: 2005 end-page: 248 ident: CR80 article-title: Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys publication-title: Contraception – volume: 124 start-page: 70 year: 2006 end-page: 76 ident: CR75 article-title: Follicular fluid vascular endothelial growth factor concentrations are increased during GnRH antagonist/FSH ovarian stimulation cycles publication-title: Eur. J. Obstet. Gynecol. Reprod. Biol. – volume: 16 start-page: 2533 year: 2001 end-page: 2539 ident: CR71 article-title: Human ovarian steroid secretion in vivo: Effects of GnRH agonist versus antagonist (cetrorelix) publication-title: Hum. Reprod. – volume: 22 start-page: 358 year: 2016 end-page: 381 ident: CR67 article-title: GnRH and GnRH receptors in the pathophysiology of the human female reproductive system publication-title: Hum. Reprod. Update – volume: 98 start-page: S210 year: 2012 ident: CR45 article-title: IVF comparison of ART outcomes in infertile PCOS women; In Vitro Maturation (IVM) vs. GnRH agonist vs. GnRH antagonist cycles publication-title: Fertil. Steril. – volume: 21 start-page: 352 year: 2006 end-page: 357 ident: CR66 article-title: Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial publication-title: Hum. Reprod. – volume: 70 start-page: 58 year: 2014 end-page: 63 ident: CR84 article-title: VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: current status publication-title: Med. J. Armed Forces India – volume: 366 start-page: l4898 year: 2019 ident: CR37 article-title: RoB 2: a revised tool for assessing risk of bias in randomised trials publication-title: BMJ – volume: 91 start-page: 1466 year: 2009 end-page: 1468 ident: CR52 article-title: What is the preferred GnRH analogue for polycystic ovary syndrome patients undergoing controlled ovarian hyperstimulation for in vitro fertilization? publication-title: Fertil. Steril. – volume: 102 start-page: e256 year: 2014 ident: CR79 article-title: Vascular endothelial growth factor (VEGF) and placental growth factor (PLGF) directly correlate with ovarian follicle size in women undergoing in vitro fertilization (IVF) publication-title: Fertil. Steril. – volume: 24 start-page: 764 year: 2009 end-page: 774 ident: CR11 article-title: Improving the patient’s experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment publication-title: Hum. Reprod. – ident: CR40 – volume: 17 start-page: 201 year: 2002 end-page: 206 ident: CR85 article-title: Quantification of Doppler signal in polycystic ovary syndrome using three-dimensional power Doppler ultrasonography: a possible new marker for diagnosis publication-title: Hum. Reprod. – volume: 21 start-page: 56 year: 2010 end-page: 65 ident: CR69 article-title: GnRH agonist and GnRH antagonist protocols in ovarian stimulation: Differential regulation pathway of aromatase expression in human granulosa cells publication-title: Reprod. Biomed. Online – volume: 11 start-page: 20 year: 2013 ident: CR9 article-title: Optimal usage of the GnRH antagonists: a review of the literature publication-title: Reprod. Biol. Endocrinol. – volume: 3 start-page: 14 year: 2005 end-page: 18 ident: CR41 article-title: A comparative study of GnRH antagonist and GnRH agonist in PCO patients undergoing IVF/ICSI cycles publication-title: Int. J. Reprod. Biomed. IRANIAN J. Reprod. Med. – volume: 2019 start-page: hoy021 year: 2019 ident: CR3 article-title: Evidence summaries and recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome: assessment and treatment of infertility publication-title: Hum. Reprod. Open – volume: 7 start-page: 13 year: 2014 end-page: 18 ident: CR4 article-title: Obstetric complications in women with IVF conceived pregnancies and polycystic ovarian syndrome publication-title: J. Hum. Reprod. Sci. – volume: 9 start-page: e91796 year: 2014 ident: CR28 article-title: Is a GnRH antagonist protocol better in PCOS patients? A Meta-Analysis of RCTs publication-title: PLoS ONE – volume: 39 start-page: 20 year: 2013 end-page: 25 ident: CR57 article-title: GnRH Antagonist IVF Protocol in PCOS publication-title: Curr. Heal. Sci. J. – volume: 18 start-page: 303 year: 1999 end-page: 313 ident: CR86 article-title: Polycystic ovarian syndrome: assessment with color Doppler angiography and three-dimensional ultrasonography. publication-title: J. Ultrasound Med. – volume: 39 start-page: 281 year: 2019 end-page: 293 ident: CR7 article-title: A meta-analysis of pregnancy-related outcomes and complications in women with polycystic ovary syndrome undergoing IVF publication-title: Reprod. Biomed. Online – volume: 87 start-page: 265 year: 2016 end-page: 270 ident: CR63 article-title: Flexible GnRH antagonist protocol vs. long GnRH agonist protocol in patients with polycystic ovary syndrome treated for IVF: Comparison of clinical outcome and embryo quality publication-title: Ginekol. Pol. – ident: CR48 – volume: 25 start-page: 365 year: 2008 end-page: 374 ident: CR61 article-title: Comparison of embryological and clinical outcome in GnRH antagonist vs. GnRH agonist protocols for in vitro fertilization in PCOS non-obese patients. A prospective randomized study publication-title: J. Assist. Reprod. Genet. – volume: 50 start-page: 84 year: 2005 end-page: 90 ident: CR59 article-title: Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: A randomized, prospective, pilot study publication-title: J. Reprod. Med. Obstet. Gynecol. – volume: 43 start-page: 248 year: 2018 end-page: 260 ident: CR13 article-title: Ovarian hyperstimulation syndrome: a narrative review of its pathophysiology, risk factors, prevention, classification, and management publication-title: Iran. J. Med. Sci. – volume: 286 start-page: 763 year: 2012 end-page: 769 ident: CR18 article-title: IVF/ICSI outcomes of the OCP plus GnRH agonist protocol versus the OCP plus GnRH antagonist fixed protocol in women with PCOS: a randomized trial publication-title: Arch. Gynecol. Obstet. – volume: 33 start-page: 1883 year: 2018 end-page: 1888 ident: CR100 article-title: The impact of a thin endometrial lining on fresh and frozen-thaw IVF outcomes: an analysis of over 40 000 embryo transfers publication-title: Hum. Reprod. – volume: 24 year: 2020 ident: CR16 article-title: Comparative study between agonist and antagonist protocols in PCOS patients undergoing ICSI: a cross-sectional study publication-title: Middle East Fertil. Soc. J. – volume: 21 start-page: 575 year: 2015 end-page: 592 ident: CR6 article-title: Pregnancy complications in women with polycystic ovary syndrome publication-title: Hum. Reprod. Update – volume: 159 start-page: 733 year: 2020 end-page: 743 ident: CR91 article-title: GnRH antagonist alters the migration of endometrial epithelial cells by reducing CKB publication-title: Reproduction – volume: 8 start-page: 118 year: 2019 end-page: 122 ident: CR98 article-title: Evaluation of endometrial receptivity by measuring HOXA-10, HOXA-11, and leukemia inhibitory factor expression in patients with polycystic ovary syndrome publication-title: Gynecol. Minim. Invasive Ther. – volume: 20 start-page: 3318 year: 2005 end-page: 3327 ident: CR96 article-title: Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles publication-title: Hum. Reprod. – volume: 17 start-page: 201 year: 2002 ident: 8400_CR85 publication-title: Hum. Reprod. doi: 10.1093/humrep/17.1.201 – volume: 2019 start-page: hoy021 year: 2019 ident: 8400_CR3 publication-title: Hum. Reprod. Open doi: 10.1093/hropen/hoy021 – volume: 9 start-page: 36 year: 2018 ident: 8400_CR78 publication-title: Biol. Sex Differ. doi: 10.1186/s13293-018-0195-5 – ident: 8400_CR40 – volume: 16 start-page: 148 year: 2015 ident: 8400_CR23 publication-title: J. Reprod. Infertil. – volume: 22 start-page: 109 year: 2007 ident: 8400_CR65 publication-title: Hum. Reprod. doi: 10.1093/humrep/del340 – volume: 33 start-page: 1270 year: 2018 ident: 8400_CR92 publication-title: Hum. Reprod. doi: 10.1093/humrep/dey119 – volume: 98 start-page: S210 year: 2012 ident: 8400_CR45 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2012.07.760 – volume: 16 start-page: 2533 year: 2001 ident: 8400_CR71 publication-title: Hum. Reprod. doi: 10.1093/humrep/16.12.2533 – volume: 67 start-page: 1305 year: 2002 ident: 8400_CR81 publication-title: Biol. Reprod. doi: 10.1095/biolreprod67.4.1305 – volume: 39 start-page: 22 year: 2012 ident: 8400_CR24 publication-title: Clin. Exp. Reprod. Med. doi: 10.5653/cerm.2012.39.1.22 – volume: 102 start-page: e256 year: 2014 ident: 8400_CR79 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2014.07.1265 – volume: 21 start-page: 575 year: 2015 ident: 8400_CR6 publication-title: Hum. Reprod. Update doi: 10.1093/humupd/dmv029 – volume: 79 start-page: 873 year: 2003 ident: 8400_CR22 publication-title: Fertil. Steril. doi: 10.1016/S0015-0282(02)04920-8 – volume: 29 start-page: 187 year: 2013 ident: 8400_CR30 publication-title: Gynecol. Endocrinol. doi: 10.3109/09513590.2012.736561 – ident: 8400_CR51 – volume: 70 start-page: 58 year: 2014 ident: 8400_CR84 publication-title: Med. J. Armed Forces India doi: 10.1016/j.mjafi.2012.03.005 – volume: 10 start-page: 721 year: 2005 ident: 8400_CR21 publication-title: Reprod. Biomed. Online doi: 10.1016/S1472-6483(10)61115-7 – volume: 21 start-page: 56 year: 2010 ident: 8400_CR69 publication-title: Reprod. Biomed. Online doi: 10.1016/j.rbmo.2010.03.017 – volume: 8 start-page: 41 year: 2010 ident: 8400_CR2 publication-title: BMC Med. doi: 10.1186/1741-7015-8-41 – volume: 21 start-page: 2521 year: 2006 ident: 8400_CR93 publication-title: Hum. Reprod. doi: 10.1093/humrep/del215 – volume: 19 start-page: 1993 year: 2004 ident: 8400_CR26 publication-title: Hum. Reprod. doi: 10.1093/humrep/deh375 – ident: 8400_CR48 – volume: 39 start-page: 166 year: 2012 ident: 8400_CR44 publication-title: Clin. Exp. Reprod. Med. doi: 10.5653/cerm.2012.39.4.166 – volume: 39 start-page: 20 year: 2013 ident: 8400_CR57 publication-title: Curr. Heal. Sci. J. – volume: 50 start-page: 84 year: 2005 ident: 8400_CR59 publication-title: J. Reprod. Med. Obstet. Gynecol. – ident: 8400_CR46 – volume: 48 start-page: 716 year: 2005 ident: 8400_CR43 publication-title: Korean J Obs. Gynecol – volume: 12 start-page: 40 year: 2009 ident: 8400_CR89 publication-title: Hum. Fertil. doi: 10.1080/14647270802621358 – volume: 18 start-page: 303 year: 1999 ident: 8400_CR86 publication-title: J. Ultrasound Med. doi: 10.7863/jum.1999.18.4.303 – volume: 94 start-page: 1832 year: 2010 ident: 8400_CR70 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2009.09.032 – volume: 13 start-page: 235 year: 2006 ident: 8400_CR64 publication-title: Reprod. Biomed. Online doi: 10.1016/S1472-6483(10)60621-9 – volume: 11 start-page: 20 year: 2013 ident: 8400_CR9 publication-title: Reprod. Biol. Endocrinol. doi: 10.1186/1477-7827-11-20 – volume: 9 start-page: e91796 year: 2014 ident: 8400_CR28 publication-title: PLoS ONE doi: 10.1371/journal.pone.0091796 – volume: 165 start-page: 61 year: 2012 ident: 8400_CR74 publication-title: Eur. J. Obstet. Gynecol. Reprod. Biol. doi: 10.1016/j.ejogrb.2012.07.014 – volume: 22 start-page: 1540 year: 2007 ident: 8400_CR25 publication-title: Hum. Reprod. doi: 10.1093/humrep/dem033 – year: 2020 ident: 8400_CR38 publication-title: Stat. Methods Med. Res. doi: 10.1177/0962280219889080 – volume: 22 start-page: 358 year: 2016 ident: 8400_CR67 publication-title: Hum. Reprod. Update doi: 10.1093/humupd/dmv059 – volume: 2 start-page: 16057 year: 2016 ident: 8400_CR1 publication-title: Nat. Rev. Dis. Primers doi: 10.1038/nrdp.2016.57 – volume: 159 start-page: 733 year: 2020 ident: 8400_CR91 publication-title: Reproduction doi: 10.1530/REP-19-0578 – volume: 5 start-page: 181 year: 2012 ident: 8400_CR54 publication-title: J. Hum. Reprod. Sci. doi: 10.4103/0974-1208.101019 – volume: 91 start-page: 1466 year: 2009 ident: 8400_CR52 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2008.07.1711 – year: 2014 ident: 8400_CR33 publication-title: Cochrane Database Syst. Rev. doi: 10.1002/14651858.CD008046.pub4 – volume: 89 start-page: 1234 year: 2008 ident: 8400_CR90 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2007.04.060 – volume: 25 start-page: 365 year: 2008 ident: 8400_CR61 publication-title: J. Assist. Reprod. Genet. doi: 10.1007/s10815-008-9249-7 – volume: 87 start-page: 265 year: 2016 ident: 8400_CR63 publication-title: Ginekol. Pol. doi: 10.17772/gp/62205 – volume: 71 start-page: 239 year: 2005 ident: 8400_CR80 publication-title: Contraception doi: 10.1016/j.contraception.2004.12.017 – volume: 82 start-page: 679 year: 2010 ident: 8400_CR97 publication-title: Biol. Reprod. doi: 10.1095/biolreprod.109.081299 – volume: 4 start-page: 70 year: 2011 ident: 8400_CR12 publication-title: J. Hum. Reprod. Sci. doi: 10.4103/0974-1208.86080 – volume: 21 start-page: 352 year: 2006 ident: 8400_CR66 publication-title: Hum. Reprod. doi: 10.1093/humrep/dei348 – volume: 24 start-page: 6 year: 2012 ident: 8400_CR31 publication-title: Reprod. Biomed. Online doi: 10.1016/j.rbmo.2011.09.017 – ident: 8400_CR35 – volume: 21 start-page: 15 year: 2014 ident: 8400_CR82 publication-title: Microcirculation doi: 10.1111/micc.12093 – volume: 40 start-page: 470 year: 2012 ident: 8400_CR87 publication-title: Ultrasound Obstet. Gynecol. doi: 10.1002/uog.11187 – volume: 6 start-page: 935 year: 2000 ident: 8400_CR83 publication-title: Mol. Hum. Reprod. doi: 10.1093/molehr/6.10.935 – volume: 13 start-page: 89 year: 2017 ident: 8400_CR5 publication-title: Women’s Heal. – volume: 11 start-page: 615957 year: 2020 ident: 8400_CR14 publication-title: Front. Endocrinol. (Lausanne). doi: 10.3389/fendo.2020.615957 – volume: 87 start-page: 834 year: 2009 ident: 8400_CR56 publication-title: Tunisie Med. – volume: 23 start-page: 560 year: 2017 ident: 8400_CR29 publication-title: Hum. Reprod. Update doi: 10.1093/humupd/dmx017 – volume: 39 start-page: 281 year: 2019 ident: 8400_CR7 publication-title: Reprod. Biomed. Online doi: 10.1016/j.rbmo.2019.03.203 – volume: 45 start-page: 135 year: 2018 ident: 8400_CR27 publication-title: Clin. Exp. Reprod. Med. doi: 10.5653/cerm.2018.45.3.135 – volume: 1 start-page: 41 year: 2015 ident: 8400_CR76 publication-title: J. Reprod. Heal. Med. doi: 10.1016/j.jrhm.2014.10.001 – volume: 53 start-page: 365 year: 2021 ident: 8400_CR94 publication-title: Acta Biochim. Biophys. Sin. (Shanghai) doi: 10.1093/abbs/gmaa173 – volume: 3 start-page: 14 year: 2005 ident: 8400_CR41 publication-title: Int. J. Reprod. Biomed. IRANIAN J. Reprod. Med. – volume: 24 start-page: 3063 year: 2009 ident: 8400_CR19 publication-title: Hum. Reprod. doi: 10.1093/humrep/dep291 – volume: 76 start-page: 718 year: 2016 ident: 8400_CR15 publication-title: Geburtshilfe Frauenheilkd. doi: 10.1055/s-0042-100206 – volume: 85 start-page: 412 year: 2006 ident: 8400_CR73 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2005.08.020 – volume: 8 start-page: 118 year: 2019 ident: 8400_CR98 publication-title: Gynecol. Minim. Invasive Ther. doi: 10.4103/GMIT.GMIT_112_18 – volume: 13 start-page: 628 year: 2006 ident: 8400_CR32 publication-title: Reprod. Biomed. Online doi: 10.1016/S1472-6483(10)60652-9 – volume: 372 year: 2021 ident: 8400_CR34 publication-title: BMJ – volume: 28 start-page: 422 year: 2012 ident: 8400_CR53 publication-title: Gynecol. Endocrinol. doi: 10.3109/09513590.2011.633661 – volume: 20 start-page: 3318 year: 2005 ident: 8400_CR96 publication-title: Hum. Reprod. doi: 10.1093/humrep/dei243 – volume: 90 start-page: S232 year: 2008 ident: 8400_CR58 publication-title: Fertil. Steril. doi: 10.1016/j.fertnstert.2008.07.565 – volume: 86 start-page: 1060 year: 2008 ident: 8400_CR55 publication-title: Tunisie Med. – volume: 24 year: 2020 ident: 8400_CR16 publication-title: Middle East Fertil. Soc. J. doi: 10.1186/s43043-019-0002-1 – volume: 22 start-page: 6 year: 2015 ident: 8400_CR99 publication-title: Reprod. Sci. doi: 10.1177/1933719114561552 – volume: 24 start-page: 764 year: 2009 ident: 8400_CR11 publication-title: Hum. Reprod. doi: 10.1093/humrep/den468 – volume: 21 start-page: 1 year: 2018 ident: 8400_CR17 publication-title: Iran. J. Obstet. Gynecol. Infertil. – volume: 124 start-page: 70 year: 2006 ident: 8400_CR75 publication-title: Eur. J. Obstet. Gynecol. Reprod. Biol. doi: 10.1016/j.ejogrb.2005.08.017 – volume: 18 start-page: 21 year: 2009 ident: 8400_CR49 publication-title: Reprod. Biomed. Online doi: 10.1016/S1472-6483(10)60420-8 – volume: 12 start-page: 58 year: 2014 ident: 8400_CR50 publication-title: Iran. J. Reprod. Med. – volume: 366 start-page: l4898 year: 2019 ident: 8400_CR37 publication-title: BMJ doi: 10.1136/bmj.l4898 – volume: 36 start-page: 605 year: 2010 ident: 8400_CR60 publication-title: J. Obstet. Gynaecol. Res. doi: 10.1111/j.1447-0756.2010.01247.x – volume: 25 start-page: 683 year: 2010 ident: 8400_CR62 publication-title: Hum. Reprod. doi: 10.1093/humrep/dep436 – ident: 8400_CR47 – volume: 374 start-page: 460 year: 1995 ident: 8400_CR95 publication-title: Nature doi: 10.1038/374460a0 – ident: 8400_CR39 – volume: 286 start-page: 763 year: 2012 ident: 8400_CR18 publication-title: Arch. Gynecol. Obstet. doi: 10.1007/s00404-012-2348-9 – volume: 24 start-page: 9424 year: 2018 ident: 8400_CR42 publication-title: Med. Sci. Monit. doi: 10.12659/MSM.913757 – volume: 29 start-page: 197 year: 2012 ident: 8400_CR10 publication-title: Balkan Med. J. doi: 10.5152/balkanmedj.2011.019 – volume: 33 start-page: 1883 year: 2018 ident: 8400_CR100 publication-title: Hum. Reprod. doi: 10.1093/humrep/dey281 – volume: 172 start-page: 1518 year: 1995 ident: 8400_CR72 publication-title: Am. J. Obstet. Gynecol. doi: 10.1016/0002-9378(95)90490-5 – volume: 7 start-page: 13 year: 2014 ident: 8400_CR4 publication-title: J. Hum. Reprod. Sci. doi: 10.4103/0974-1208.130802 – volume: 18 start-page: 2698 year: 2003 ident: 8400_CR20 publication-title: Hum. Reprod. doi: 10.1093/humrep/deg516 – volume: 58 start-page: 888 year: 1992 ident: 8400_CR8 publication-title: Fertil. Steril. doi: 10.1016/S0015-0282(16)55430-2 – volume: 14 start-page: 737 year: 2007 ident: 8400_CR68 publication-title: Reprod. Sci. doi: 10.1177/1933719107310707 – ident: 8400_CR36 – volume: 43 start-page: 248 year: 2018 ident: 8400_CR13 publication-title: Iran. J. Med. Sci. – volume: 21 start-page: 52 year: 2016 ident: 8400_CR88 publication-title: Middle East Fertil. Soc. J. doi: 10.1016/j.mefs.2015.11.001 – volume: 6 start-page: 209 year: 2005 ident: 8400_CR77 publication-title: Genome Biol. doi: 10.1186/gb-2005-6-2-209 |
| SSID | ssj0000529419 |
| Score | 2.550786 |
| SecondaryResourceType | review_article |
| Snippet | Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during In-Vitro... Abstract Gonadotropin-releasing hormone (GnRH) analogues are commonly used in clinical practice to prevent premature luteinizing hormone (LH) surge during... |
| SourceID | doaj pubmedcentral proquest pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 4456 |
| SubjectTerms | 692/699/2732/1577 692/700 Agonists Birth rate Clinical Protocols Clinical trials Endometrium Female Fertilization in Vitro - methods Gonadotropin-Releasing Hormone Gonadotropins Hormone Antagonists Humanities and Social Sciences Humans In vitro fertilization Luteinizing hormone Meta-analysis multidisciplinary Oocytes Ovarian Hyperstimulation Syndrome Ovaries Ovulation Induction - methods Pituitary (anterior) Polycystic ovary syndrome Polycystic Ovary Syndrome - complications Polycystic Ovary Syndrome - drug therapy Pregnancy Pregnancy Rate PROSPERO (International Prospective Register of Systematic Reviews) Risk assessment Science Science (multidisciplinary) Sperm Injections, Intracytoplasmic |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELfQJCReEN8EBjok3iBqHDuxszeoKC0SPABDe7Nsx94mlWRa20nZ_8P_ydlJu3Z8vfBqn6XT3Tl3lzv_jpCXBaszg445tZh6hRFmWWqYCB0ATBfMuNLHR2EfP5XTQ_7hqDjaGvUVesJ6eOBecCMrvRbo06xjjkttpZbU-Vp4nZWOiwi2nVXZVjLVo3rnFafV8EomY3K0QE8VXpNh7pVhUpOllzueKAL2_y7K_LVZ8lrFNDqiyR1ye4gg4U3P-V1ywzX3yM1-pmR3n_wYb_WRw_vm8xRQePq4DRC5EGAZWtT9AkI7xmoB87Y5HqiukcBpA7Nvk9Fs_GUGtgvdc9B6OGvnne0CujO0F_q8gzXmAUQwhwPQcIUODf3LGOSghu9uqVM9YKA8IIeTd1_H03SYxZBajOmWqc8KY1FxmgthSxt-nxaalcKKwuTMMEu9cFrkTHNcCrOIdGG5Lag2UpjasIdkr2kb95iAtNxRZ7yt6orzWsqKGs9Kp0ubS09tQuhaL8oOQOVhXsZcxYI5k6rXpUJdqqhLdZmQV5szZz1Mx1-p3wZ1bygDxHZcQMNTg-GpfxleQvbXxqKGe79QOQZ8oRRc8oS82GzjjQ1lGN24dhVo4neTVkjzqLetDScYDlc5ZtgJETtWt8Pq7k5zehJRwSVm0rnAk6_X9nnF1p9F8eR_iOIpuZXHi8VSWuyTveX5yj3DWG1pnsdr-RP7yz9E priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Journals: Open Access dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9QwDI_GEBIvE98UNhQk3qCsadImRUITnDjukOABOLS3KEmTY9KtHfeB6P4f_k-ctL1x49hr40hubDd2bf-M0LOMlomGizk2EHr5EWZJrCn3FQBUZVTb3IWmsI-f8tGEfTjOjndQP-6oO8DF1tDOz5OazGcvf_1ojsDgX7ct4-JwAZeQbxSDsCqBeCWJz6-h6yFf5Ev5One_xfpOC0aKrndm-9aN-ynA-G_zPf8tobyURw3X0_AW2uv8SvymVYTbaMdWd9CNdtJkcxf9HvxVXY7fV59HGI5UTWsPnIs9WEMNGrHAvkhjtcCzupp2VJdI8EmFx9-Gh-PBlzE2ja-pw7XDZ_WsMY3HfMb1TzVvcI-EgAPEwyus8AVmNG77ZYCDEp_apYpVh4xyD02G774ORnE3oSE24OktY5dk2oA4FePc5Mb_VM0UzbnhmU6ppoY4bhVPqWLwyE8oUplhJiNKC65LTe-j3aqu7EOEhWGWWO1MURaMlUIURDuaW5WbVDhiIkR6uUjTwZf7KRozGdLoVMhWlhJkKYMs5XmEnq_3nLXgHVdSv_XiXlN64O3woJ5PZWfH0ginOLhYxlLLhDJCCWJdyZ1Kcst4HqH9Xllkr8wyBTfQJ4hzFqGn62WwY5-cUZWtV54mfE1JATQPWt1acwJOcpFC3B0hvqF1G6xurlQn3wNWuID4OuWw80Wvnxds_f8oHl39Fo_RzTSYDI1Jto92l_OVPQDfbKmfBIP7A60WONg priority: 102 providerName: Scholars Portal – databaseName: Springer Nature HAS Fully OA dbid: AAJSJ link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LbxMxELZKKiQuiDdLCzISN1h1vfauvdxCREgiwYFS1Jtle-20Utit8qiU_h_-J2Pvo6QUJK72WBp5xvaMZ-YbhN5ktEw0PMyxAdfLtzBLYk25zwCgKqPa5i4UhX3-kk9O2Ow0O91DaVcLE5L2A6RluKa77LCjFTw0vhgMXKcEfJIkvrqD9gWH63eA9ofD2fGs_1nxsStGirZCJqHilsU7r1AA67_NwvwzUfJGtDQ8QuMH6H5rPeJhw-9DtGerR-hu009y-xj9HP2WQ44_VV8nGDZOzWsPj4s9JEMNcl9hn4qxWeFFXc1bqhsk-LzC0-_jo-noeIrN1u8Nrh2-qBdbs_XIzri-VMst7vAOcAByeI8VvkaGxk1VDHBQ4h92rWLV4p88QSfjj99Gk7jtwxAbsOfWsUsybUBoinFucuO_TjNFc254plOqqSGOW8VTqhgM-T5EKjPMZERpwXWp6VM0qOrKPkdYGGaJ1c4UZcFYKURBtKO5VblJhSMmQqSTizQtSLnvlbGQIVhOhWxkKUGWMshSXkXobb_mooHo-Cf1By_untLDa4eBejmXrbpJI5ziYEgZSy0TyggliHUldyrJLeN5hA47ZZHtmV_JFIw9HwbOWYRe99NwWn0IRlW23niacGeSAmieNbrVcwKmcJGCdx0hvqN1O6zuzlTnZwERXIAXnXJY-a7Tz2u2_r4VL_6P_ADdS8MRojHJDtFgvdzYl2CRrfWr9gj-AmXYNR0 priority: 102 providerName: Springer Nature |
| Title | Conventional GnRH antagonist protocols versus long GnRH agonist protocol in IVF/ICSI cycles of polycystic ovary syndrome women: a systematic review and meta-analysis |
| URI | https://link.springer.com/article/10.1038/s41598-022-08400-z https://www.ncbi.nlm.nih.gov/pubmed/35292717 https://www.proquest.com/docview/2639130264 https://www.proquest.com/docview/2640048194 https://pubmed.ncbi.nlm.nih.gov/PMC8924277 https://doaj.org/article/c8fa7910ce3e48ac8a81efd7fa06e476 |
| Volume | 12 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgExIviG8KozISbxA1jp3Y4QV10UpbaRPaGOpbZDtOmVSS0rRI3f_D_8nZcVs6YC-J5FwkJ3dn35d_h9DbmBahgo050OB62RZmYaAotxUAVMZUmaR0h8JOz5LhJRtP4okPuDW-rHKzJrqFuqi1jZH3IthKbZItYR_nPwLbNcpmV30LjbvokIAlYls38AnfxlhsFouR1J-VCanoNbBf2TNl4IGF4NqEwfXefuRg-_9la_5dMnkjb-q2o8FD9MDbkbjfMv4RumOqx-he21ly_QT9yv6oJsefqvMhhl8op7UFysUWnKEGCWiwLcpYNXhWV1NPdYMEX1V49HXQG2UXI6zXtoYO1yWe17O1XluMZ1z_lIs13iAfYAfp8AFLvMOIxu35GJhBgb-bpQykR0J5ii4HJ1-yYeA7MgQaLLtlUIax0sA-yTjXibZB1FjShGseq4gqqknJjeQRlQyGbEciGWumYyKV4KpQ9Bk6qOrKvEBYaGaIUaVOi5SxQoiUqJImRiY6EiXRHUQ2fMm1hyu3XTNmuUubU5G3vMyBl7njZX7dQe-278xbsI5bqY8tu7eUFmjbDdSLae71NteilBxMKm2oYUJqIQUxZcFLGSaG8aSDjjbCknvtb_KdrHbQm-1j0FubjJGVqVeWxq2eJAWa561sbWcCRnEagZ_dQXxP6vamuv-kuvrmsMEF-NMRhzffb-RzN63__4qXt3_FK3Q_cipDAxIfoYPlYmVegy22VF2ncF102O-PL8ZwPz45-3wOo1mSdV18A66nTPwGc9A7NA |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELdGJwQviG8KA4wETxA1iZ3YQZoQKyst-xAa27Q3YztOmVSS0g9Q9v_wb_C3cXaSlg7Y216TS-Tkzvfhu_sdQs8jkvoKDLOnIfSyI8x8TxFmKwCIjIgyceaawvb24_4R_XASnayhX00vjC2rbHSiU9Rpoe0ZeScEU2qTbDF9M_7m2alRNrvajNCQ9WiFdNNBjNWNHTum_AEh3HRz8A74_SIMe9uH3b5XTxnwNHgrMy_zI6VhSZIypmNtDwYjSWKmWaRCoogOMmYkC4mkcMlO2ZGRpjoKpOJMpYrAe6-gdWoPUFpofWt7_-PB4pTH5tFokNTdOj7hnSlYTNvVBjGgD8GV752tWEQ3OOBf3u7fRZvnMrfOIPZuohu1J4vfVqJ3C62Z_Da6Ws22LO-gn90_6tnx-_ygj4GJclhYqF5s4SEKkMEptmUh8ykeFfmwpjpHgk9zPDjudQbdTwOsS1vFh4sMj4tRqUuLMo2L73JS4gZ7ATtQiddY4iVKNa46dGAFKf5qZtKTNRbLXXR0Kdy6h1p5kZsHCHNNTWBUppM0oTTlPAlURmIjYx3yLNBtFDR8EboGTLdzO0bCJe4JFxUvBfBSOF6KszZ6uXhmXMGFXEi9Zdm9oLRQ3-5CMRmKWnMIzTPJwKnThhjKpeaSByZLWSb92FAWt9FGIyyi1j9TsdwtbfRscRs0h00HydwUc0vj9HeQAM39SrYWKwG3PAkh0m8jtiJ1K0tdvZOffnHo5Bwi-pDBk68a-Vwu6_-_4uHFX_EUXesf7u2K3cH-ziN0PXTbh3hBtIFas8ncPAbPcKae1NsPo8-XveN_A9fPeSw |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwELfGJhAviG8KA4wETxA1iZPYQZrQ1q20DKppMLS3YDt2mVSS0g9Q9v_wz-yv4uw4LR2wt70ml8jJne_Dd_c7hJ7HJPcFGGZPQuhlRpj5niDUVAAQHhOhEm2bwj4Mkt5R9O44Pl5DZ00vjCmrbHSiVdR5Kc0ZeTsEU2qSbEnU1q4s4mC3-2b83TMTpEymtRmnwd2YhXzLwo25Jo99Vf2EcG661d8F3r8Iw-7ep07PcxMHPAmey8zTfiwkLI9HlMpEmkPCmJOEShqLkAgiA00VpyHhEVwyE3d4LCMZB1wwKnJB4L1X0AYFqw-B4MbO3uDgcHHiY3JqUZC6zh2fsPYUrKfpcIN40IdAy_dOV6yjHSLwL8_37wLOc1lcaxy7N9EN59Xi7VoMb6E1VdxGV-s5l9Ud9KvzR207flsc9jAwlA9LA9uLDVRECfI4xaZEZD7Fo7IYOqpzJPikwP3P3Xa_87GPZWUq-nCp8bgcVbIyiNO4_MEnFW5wGLAFmHiNOV4iVuO6WwdWkONvasY97nBZ7qKjS-HWPbRelIV6gDCTkQqU0DLN0yjKGUsDoUmieCJDpgPZQkHDl0w68HQzw2OU2SQ-YVnNywx4mVleZqct9HLxzLiGDrmQesewe0FpYL_thXIyzJwWySTTnIKDJxVREeOScRYonVPN_URFNGmhzUZYMqeLptly57TQs8Vt0CImNcQLVc4NjdXlQQo092vZWqwEXPQ0hKi_heiK1K0sdfVOcfLVIpUziO5DCk--auRzuaz__4qHF3_FU3QNdn72vj_Yf4Suh3b3EC-IN9H6bDJXj8FJnIknbvdh9OWyN_xvjTB9cA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Conventional+GnRH+antagonist+protocols+versus+long+GnRH+agonist+protocol+in+IVF%2FICSI+cycles+of+polycystic+ovary+syndrome+women%3A+a+systematic+review+and+meta-analysis&rft.jtitle=Scientific+reports&rft.au=Kadoura+Sally&rft.au=Alhalabi+Marwan&rft.au=Nattouf+Abdul+Hakim&rft.date=2022-03-15&rft.pub=Nature+Publishing+Group&rft.eissn=2045-2322&rft.volume=12&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-022-08400-z&rft.externalDBID=HAS_PDF_LINK |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon |